Literature DB >> 23034357

Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies.

Marisol Simões1, Luiz Antonio B Camacho, Anna M Y Yamamura, Emily Hime Miranda, Ana Carolina R A Cajaraville, Marcos da Silva Freire.   

Abstract

Yellow fever is a disease caused by the prototype virus of the genus Flavivirus and remains endemic in tropical forest regions from Africa and South America, despite the availability of effective vaccines. These are capable of inducing a rapid specific immune response, with the formation of neutralizing antibodies that appear early, are protective and long lasting. The Plaque Reduction Neutralization Test is considered the most sensitive and specific test for quantification of neutralizing antibodies, and the reference method for assessing the protective immune response after vaccination. This study evaluated the reliability (repeatability and reproducibility) and accuracy (sensitivity, specificity and overall accuracy) of micro-PRNT50 and compared its performance with the micro-PRNT90. Although the micro-PRNT50 has showed satisfactory levels of reliability (ICCs ranged from 0.62 to 0.NorNormas e Manuais Técnicosas e Manuais Técnicos6 for repeatability and 0.72 for reproducibility) and accuracy (sensitivity of 91.1%, specificity of 72.9% and overall accuracy of 78%), the micro-PRNT90 showed higher performance, with ICCs for repeatability ranged from 0.78 to 0.79 and 0.81 for reproducibility, sensitivity of 100%, specificity of 94.7% and overall accuracy of 95%. Modifications in the test methodology and changes in the classification criteria in the readings of the results obtained will be important to improve the accuracy of micro-PRNT.
Copyright © 2012 The International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23034357     DOI: 10.1016/j.biologicals.2012.09.005

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  24 in total

Review 1.  Advances and controversies in yellow fever vaccination.

Authors:  Emile F F Jonker; Leonardus G Visser; Anna H Roukens
Journal:  Ther Adv Vaccines       Date:  2013-11

2.  Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.

Authors:  Stephen Tottey; Yoko Shoji; R Mark Jones; Jessica A Chichester; Brian J Green; Konstantin Musiychuk; Huaxin Si; Slobodanka D Manceva; Amy Rhee; Moneim Shamloul; Joey Norikane; Rosane C Guimarães; Elena Caride; Andrea N M R Silva; Marisol Simões; Patricia C C Neves; Renato Marchevsky; Marcos S Freire; Stephen J Streatfield; Vidadi Yusibov
Journal:  Am J Trop Med Hyg       Date:  2017-11-30       Impact factor: 2.345

3.  A High-Throughput Yellow Fever Neutralization Assay.

Authors:  Madina Rasulova; Thomas Vercruysse; Jasmine Paulissen; Catherina Coun; Vanessa Suin; Leo Heyndrickx; Ji Ma; Katrien Geerts; Jolien Timmermans; Niraj Mishra; Li-Hsin Li; Dieudonné Buh Kum; Lotte Coelmont; Steven Van Gucht; Hadi Karimzadeh; Julia Thorn-Seshold; Simon Rothenfußer; Kevin K Ariën; Johan Neyts; Kai Dallmeier; Hendrik Jan Thibaut
Journal:  Microbiol Spectr       Date:  2022-06-07

4.  Persistence of Yellow Fever vaccine-induced antibodies after cord blood stem cell transplant.

Authors:  Vivian Iida Avelino-Silva; Marcos da Silva Freire; Vanderson Rocha; Celso Arrais Rodrigues; Yana Sarkis Novis; Ester C Sabino; Esper Georges Kallas
Journal:  Hum Vaccin Immunother       Date:  2015-11-30       Impact factor: 3.452

5.  Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.

Authors:  Ismael Artur da Costa-Rocha; Ketty Lysie Libardi Lira Machado; Ana Carolina Campi-Azevedo; Andréa Teixeira-Carvalho; Vanessa Peruhype-Magalhães; Sheila Maria Barbosa de Lima; Emily Hime Miranda; Gisela Freitas Trindade; Thays Zanon Casagrande; Samira Tatiyama Miyamoto; Sávio Carvalho Deotti; Rafaela Villa Real Barbosa; Priscila Costa Martins Rocha; Erica Vieira Serrano; Valquiria Garcia Dinis; Sônia Alves Gouvêa; Maria Bernadete Renoldi de Oliveira Gavi; Lidia Balarini da Silva; Ruben Horst Duque; Ana Paula Espíndula Gianordoli; Maria de Fatima Bissoli; Maria da Penha Gomes Gouvea; Lauro Ferreira da Silva Pinto-Neto; Ana Paula Neves Burian; Francieli Fontana Sutile Tardetti Fantinato; Gecilmara Salviato Pileggi; Licia Maria Henrique da Mota; Valéria Valim; Olindo Assis Martins-Filho
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

6.  Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults.

Authors:  Karina Takesaki Miyaji; Vivian Iida Avelino-Silva; Marisol Simões; Marcos da Silva Freire; Carlos Roberto de Medeiros; Patrícia Emilia Braga; Maria Angélica Acalá Neves; Marta Heloisa Lopes; Esper Georges Kallas; Ana Marli Christovam Sartori
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-03       Impact factor: 1.846

7.  Multi-parameter approach to evaluate the timing of memory status after 17DD-YF primary vaccination.

Authors:  Christiane Costa-Pereira; Ana Carolina Campi-Azevedo; Jordana Grazziela Coelho-Dos-Reis; Vanessa Peruhype-Magalhães; Márcio Sobreira Silva Araújo; Lis Ribeiro do Vale Antonelli; Cristina Toscano Fonseca; Jandira Aparecida Lemos; Luiz Cosme Cote Malaquias; Matheus de Souza Gomes; Laurence Rodrigues Amaral; Maria Rios; Caren Chancey; Harold Richard Persi; Jorge Marcelo Pereira; Maria de Lourdes de Sousa Maia; Marcos da Silva Freire; Reinaldo de Menezes Martins; Akira Homma; Marisol Simões; Anna Yoshida Yamamura; Roberto Henrique Guedes Farias; Alessandro Pecego Martins Romano; Carla Magda Domingues; Pedro Luiz Tauil; Pedro Fernando Costa Vasconcelos; Iramaya Rodrigues Caldas; Luiz Antônio Camacho; Andrea Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  PLoS Negl Trop Dis       Date:  2018-06-07

8.  Booster dose after 10 years is recommended following 17DD-YF primary vaccination.

Authors:  Ana Carolina Campi-Azevedo; Christiane Costa-Pereira; Lis R Antonelli; Cristina T Fonseca; Andréa Teixeira-Carvalho; Gabriela Villela-Rezende; Raiany A Santos; Maurício A Batista; Fernanda M Campos; Luiza Pacheco-Porto; Otoni A Melo Júnior; Débora M S H Hossell; Jordana G Coelho-dos-Reis; Vanessa Peruhype-Magalhães; Matheus F Costa-Silva; Jaquelline G de Oliveira; Roberto H Farias; Tatiana G Noronha; Jandira A Lemos; Vanessa dos R von Doellinger; Marisol Simões; Mirian M de Souza; Luiz C Malaquias; Harold R Persi; Jorge M Pereira; José A Martins; Marcos Dornelas-Ribeiro; Aline de A Vinhas; Tatiane R Alves; Maria de L Maia; Marcos da S Freire; Reinaldo de M Martins; Akira Homma; Alessandro P M Romano; Carla M Domingues; Pedro L Tauil; Pedro F Vasconcelos; Maria Rios; Iramaya R Caldas; Luiz A Camacho; Olindo Assis Martins-Filho
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

9.  CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients.

Authors:  Vivian I Avelino-Silva; Karina T Miyaji; Peter W Hunt; Yong Huang; Marisol Simoes; Sheila B Lima; Marcos S Freire; Helio H Caiaffa-Filho; Marisa A Hong; Dayane Alves Costa; Juliana Zanatta C Dias; Natalia B Cerqueira; Anna Shoko Nishiya; Ester Cerdeira Sabino; Ana M Sartori; Esper G Kallas
Journal:  PLoS Negl Trop Dis       Date:  2016-12-12

10.  Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype.

Authors:  Séverine Mercier-Delarue; Christine Durier; Nathalie Colin de Verdière; Jean-Dominique Poveda; Vincent Meiffrédy; Maria Dolores Fernandez Garcia; Stéphane Lastère; Raymond Césaire; Jean-Claude Manuggera; Jean-Michel Molina; Ali Amara; François Simon
Journal:  PLoS One       Date:  2017-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.